Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 1

Conditions

Prostatic Neoplasms 4Pancreatic Neoplasms 3Carcinoma, Hepatocellular 2Squamous Intraepithelial Lesions 1Skin Neoplasms 1Pancreatic Adenocarcinoma Locally Advanced 1Melanoma 1Lymphatic Metastasis 1Liver Diseases 1HIV Seropositivity 1

Interventions

pembrolizumab 16Nivolumab 15Ipilimumab 12cemiplimab 10aldesleukin 6Interleukin-2 6Cyclophosphamide 6fludarabine 5fludarabine phosphate 4encorafenib 4binimetinib 4Blood Specimen Collection 4avelumab 3Sirolimus 3trametinib 2spartalizumab 2lifileucel 2dabrafenib 2atezolizumab 2Vemurafenib 2Surgical Procedures, Operative 2Specimen Handling 2Radiotherapy 2Prednisone 2Niacinamide 2Exercise 2Everolimus 2Dermoscopy 2Biopsy 2urelumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Skin Neoplasms × Electroporation × 1 year × Clear all
NCT04526730 2026-02-20

Neoadjuvant Immunotherapy With Tavo + Electroporation in Combination With Nivo. in Melanoma Patients

H. Lee Moffitt Cancer Center and Research Institute

Phase 2 Completed
17 enrolled 11 charts
Dermatologic

Melanoma, Skin Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡